You have read all your free articles, to continue reading subscribe to read the rest of this content.
BioInvent’s collaboration partner ThromboGenics initiates Phase II study with the drug candidate THR-317. BioInvent International AB announces today that the company’s collaboration partner ThromboGenics NV reports that the first patients have been enrolled in a study with the drug candidate Already a subscriber Login You have read all your free…
Alligator Bioscience has presented the status of its ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer. This far, doses of 400 mg (about 6 mg/kg) have been evaluated in the ongoing study and the current dosing is Already a subscriber…
Lundbeck has announced positive results from the DELIVER study assessing the efficacy and safety of Vyepti (eptinezumab) 100mg and 300mg IV infusion in patients with chronic or episodic migraine who had experienced two to four previous preventive treatment failures due to lack of efficacy or intolerAlready a subscriber Login You…
Elypta announces the enrollment of the first patient in the newly initiated AURORAX-0093A (AUR93A) study. AUR93A is intended to explore Elypta’s metabolism-based liquid biopsy platform for the prognosis of muscle-invasive bladder cancer (MIBC) before neo-adjuvant chemotherapy. The first patientAlready a subscriber Login You have read all your free articles, to…
